| MeSH term | MeSH ID | Detail |
|---|---|---|
| Asthenia | D001247 | 5 associated lipids |
| Body Weight | D001835 | 333 associated lipids |
| Brain Diseases | D001927 | 27 associated lipids |
| Breast Neoplasms | D001943 | 24 associated lipids |
| Bronchial Spasm | D001986 | 18 associated lipids |
| Colonic Neoplasms | D003110 | 161 associated lipids |
| Hyperplasia | D006965 | 34 associated lipids |
| Hypopharyngeal Neoplasms | D007012 | 1 associated lipids |
| Leukemia | D007938 | 74 associated lipids |
| Leukemia P388 | D007941 | 43 associated lipids |
MAYTANSINE
MAYTANSINE is a lipid of Polyketides (PK) class. Maytansine is associated with abnormalities such as Myelosuppression and BOSLEY-SALIH-ALORAINY SYNDROME. The involved functions are known as Mutation, Agent, Polymerization, Cell Cycle Arrest and Drug Kinetics. Maytansine often locates in Cytoplasm, Hepatic, Lysosomes, Cell surface and Microtubules. The associated genes with MAYTANSINE are ABCB1 gene, HM13 gene, CNN1 gene, CYP2C8 gene and CYP2D6 gene. The related lipids are Valerates. The related experimental models are Xenograft Model.
Cross Reference
Introduction
To understand associated biological information of MAYTANSINE, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with MAYTANSINE?
MAYTANSINE is suspected in Myelosuppression, BOSLEY-SALIH-ALORAINY SYNDROME and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with MAYTANSINE
PubChem Associated disorders and diseases
What pathways are associated with MAYTANSINE
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with MAYTANSINE?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with MAYTANSINE?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with MAYTANSINE?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with MAYTANSINE?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with MAYTANSINE?
Xenograft Model
Xenograft Model are used in the study 'IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.' (Ab O et al., 2015).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with MAYTANSINE
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Shen BQ et al. | Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. | 2012 | Nat. Biotechnol. | pmid:22267010 |
| DeFrancesco L | Drug pipeline: 1Q13. | 2013 | Nat. Biotechnol. | pmid:23752422 |
| Beck A et al. | Strategies and challenges for the next generation of antibody-drug conjugates. | 2017 | Nat Rev Drug Discov | pmid:28303026 |
| Zolot RS et al. | Antibody-drug conjugates. | 2013 | Nat Rev Drug Discov | pmid:23535930 |
| Villanueva MT | Targeted therapies: TH3RESA trial, overcoming hurdles in breast cancer. | 2014 | Nat Rev Clin Oncol | pmid:24913372 |
| Kang Q et al. | Biosynthesis of 3,5-AHBA-derived natural products. | 2012 | Nat Prod Rep | pmid:22193711 |
| Menchon G et al. | A fluorescence anisotropy assay to discover and characterize ligands targeting the maytansine site of tubulin. | 2018 | Nat Commun | pmid:29844393 |
| Adams SR et al. | Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize. | 2016 | Nat Commun | pmid:27698471 |
| Zhong P et al. | cRGD-installed docetaxel-loaded mertansine prodrug micelles: redox-triggered ratiometric dual drug release and targeted synergistic treatment of B16F10 melanoma. | 2017 | Nanotechnology | pmid:28574851 |
| He X et al. | Inflammatory Monocytes Loading Protease-Sensitive Nanoparticles Enable Lung Metastasis Targeting and Intelligent Drug Release for Anti-Metastasis Therapy. | 2017 | Nano Lett. | pmid:28758755 |
| Teicher BA and Doroshow JH | The promise of antibody-drug conjugates. | 2012 | N. Engl. J. Med. | pmid:23134386 |
| Verma S et al. | Trastuzumab emtansine for HER2-positive advanced breast cancer. | 2012 | N. Engl. J. Med. | pmid:23020162 |
| Hamblett KJ et al. | Altering Antibody-Drug Conjugate Binding to the Neonatal Fc Receptor Impacts Efficacy and Tolerability. | 2016 | Mol. Pharm. | pmid:27248573 |
| Hong EE et al. | Design of Coltuximab Ravtansine, a CD19-Targeting Antibody-Drug Conjugate (ADC) for the Treatment of B-Cell Malignancies: Structure-Activity Relationships and Preclinical Evaluation. | 2015 | Mol. Pharm. | pmid:25856201 |
| Widdison W et al. | Metabolites of antibody-maytansinoid conjugates: characteristics and in vitro potencies. | 2015 | Mol. Pharm. | pmid:25826705 |
| Salomon PL and Singh R | Sensitive ELISA Method for the Measurement of Catabolites of Antibody-Drug Conjugates (ADCs) in Target Cancer Cells. | 2015 | Mol. Pharm. | pmid:25738394 |
| Fishkin N | Maytansinoid-BODIPY Conjugates: Application to Microscale Determination of Drug Extinction Coefficients and for Quantification of Maytansinoid Analytes. | 2015 | Mol. Pharm. | pmid:25738231 |
| Goldmacher VS et al. | Statistics of the distribution of the abundance of molecules with various drug loads in maytansinoid antibody-drug conjugates. | 2015 | Mol. Pharm. | pmid:25635630 |
| Barginear MF et al. | Trastuzumab-DM1: a clinical update of the novel antibody-drug conjugate for HER2-overexpressing breast cancer. | 2012 | Mol. Med. | pmid:23196784 |
| Oroudjev E et al. | Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability. | 2010 | Mol. Cancer Ther. | pmid:20937595 |